Core Insights - Merck has showcased its commitment to innovation and collaboration in the healthcare sector at the 8th China International Import Expo, emphasizing its theme of "Innovative Science, Healthy Future" [1] Group 1: Product and Pipeline Highlights - Merck is displaying approximately 30 approved drugs and vaccines in China, covering areas such as oncology, anti-infection, diabetes, and rare diseases, including several innovative drugs making their debut at the expo [1] - The company plans to introduce over 40 new products and indications to China in the next five years, with ongoing clinical research in multiple therapeutic areas [1] Group 2: Collaborations and Initiatives - Over the past three years, Merck has engaged in several R&D collaborations with five local pharmaceutical companies, focusing on cardiovascular, metabolic, and oncology fields [1] - The establishment of the Merck China Innovation Collaboration Center (MCICC) on November 1, 2024, aims to enhance cooperation with China's life sciences innovation ecosystem, promoting rapid and high-quality clinical translation of breakthrough innovations from China [1] Group 3: Animal Health Segment - In the animal health sector, Merck will showcase products and solutions covering five major business areas: pets, poultry, pigs, ruminants, and aquaculture [2] - The company will also host several thematic events focusing on key areas such as oncology, rare diseases, and public health [2]

Core Insights - Merck has showcased its commitment to innovation and health in China for the seventh consecutive year at the China International Import Expo, emphasizing its role in saving lives and improving health outcomes [1] Group 1: Product Offerings - At this year's expo, Merck will display approximately 30 approved drugs and vaccines in China, covering areas such as oncology, anti-infection, diabetes, and rare diseases, including several innovative drugs making their debut [2] - Merck is advancing multiple clinical studies in various therapeutic areas in China and plans to introduce over 40 new products and indications in the next five years [2] Group 2: Vaccines and Cancer Treatment - As a leader in vaccine innovation, Merck has transferred hepatitis B vaccine production technology to China at zero profit since 1989 and has launched multiple antiviral and antibacterial vaccines, protecting over 50 million women with its HPV vaccines [3] - In cancer treatment, Merck's immunotherapy product line is expected to have 32 indications approved in China by August 2025, targeting high-mortality cancers and aiming to create a future where cancer is treatable [3] Group 3: Collaborations and Initiatives - Over the past three years, Merck has engaged in several R&D collaborations with local pharmaceutical companies in areas such as cardiovascular, metabolic, and oncology [3] - The establishment of the Merck China Innovation Cooperation Center (MCICC) on November 1, 2024, aims to enhance collaboration within China's life sciences ecosystem and accelerate the clinical translation of innovative results [3] Group 4: Animal Health and Community Engagement - Merck promotes animal health through its comprehensive product offerings for pets, poultry, pigs, ruminants, and aquaculture, adhering to the principle that "science makes animals healthier" [4] - The company has initiated significant community health projects, including the "Key to Life" cancer immunotherapy patient assistance program and the "VHL Uncommon" patient assistance project, demonstrating its long-term commitment to improving patient accessibility in China [4]

Group 1 - The core viewpoint of the article highlights that Merck's (MRK) stock price dropped by 5.5% on July 29, closing at $79.44 per share, with a total market capitalization of $199.48 billion [1][2] - Financial data shows that as of June 30, 2025, Merck's total revenue amounted to $31.335 billion, reflecting a year-on-year decrease of 1.73% [1][2] - The net profit attributable to shareholders for the fiscal year 2025 was reported at $9.506 billion, which represents a decline of 6.96% compared to the previous year [2] Group 2 - Merck is identified as a leading global biopharmaceutical company focused on providing drugs and vaccines for some of the world's most challenging diseases [2] - The company continues to be at the forefront of biopharmaceutical research, aiming to advance prevention and treatment for diseases that threaten populations worldwide, including cancer, heart disease, emerging animal diseases, Alzheimer's, and infectious diseases such as HIV and Ebola [2]